WO2012007555A3 - New ziprasidone salts and methods of their formation - Google Patents

New ziprasidone salts and methods of their formation Download PDF

Info

Publication number
WO2012007555A3
WO2012007555A3 PCT/EP2011/062080 EP2011062080W WO2012007555A3 WO 2012007555 A3 WO2012007555 A3 WO 2012007555A3 EP 2011062080 W EP2011062080 W EP 2011062080W WO 2012007555 A3 WO2012007555 A3 WO 2012007555A3
Authority
WO
WIPO (PCT)
Prior art keywords
ziprasidone
new
formation
methods
salt
Prior art date
Application number
PCT/EP2011/062080
Other languages
French (fr)
Other versions
WO2012007555A2 (en
Inventor
Marek Leszek Glowka
Waldemar Maniukiewicz
Monika Oracz
Lech Swinder
Karol Sagol
Marcin Szulc
Original Assignee
Zaklady Farmaceutyczne Polpharma, S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farmaceutyczne Polpharma, S. A. filed Critical Zaklady Farmaceutyczne Polpharma, S. A.
Publication of WO2012007555A2 publication Critical patent/WO2012007555A2/en
Publication of WO2012007555A3 publication Critical patent/WO2012007555A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New salts of ziprasidone and their solvates were disclosed, in particular in crystalline form. More specifically, the present invention relates to a ziprasidone salt selected from a group comprising ziprasidone succinate and ziprasidone ascorbate, a process for the manufactured of the ziprasidone salt and a pharmaceutical composition comprises said salt.
PCT/EP2011/062080 2010-07-14 2011-07-14 New ziprasidone salts and methods of their formation WO2012007555A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL391810A PL391810A1 (en) 2010-07-14 2010-07-14 New ziprasidone salts and processes for the preparation thereof
PLP391810 2010-07-14

Publications (2)

Publication Number Publication Date
WO2012007555A2 WO2012007555A2 (en) 2012-01-19
WO2012007555A3 true WO2012007555A3 (en) 2012-03-15

Family

ID=44630161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/062080 WO2012007555A2 (en) 2010-07-14 2011-07-14 New ziprasidone salts and methods of their formation

Country Status (2)

Country Link
PL (1) PL391810A1 (en)
WO (1) WO2012007555A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020929A2 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (en) 1987-03-02 1994-02-23 Pfizer PIPERAZINIL HETERO-CYCLIC COMPOUNDS AND PROCEDURE FOR THE PREPARATION
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK0790236T3 (en) 1996-02-13 2004-02-23 Pfizer Prodrugs of 5- (2- (4- (1,2-benzisothiazol-3-yl) -1-piperazinyl) ethyl) -6-chloro-1,3-dihydro-2H-indol-2-one

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020929A2 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: 10.1007/3-540-69178-2_5 *

Also Published As

Publication number Publication date
WO2012007555A2 (en) 2012-01-19
PL391810A1 (en) 2012-01-16

Similar Documents

Publication Publication Date Title
AP3346A (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
PL3683209T3 (en) Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
RS56891B1 (en) 2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis
WO2012122011A3 (en) Amino-quinolines as kinase inhibitors
IN2014KN00948A (en)
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
HK1198535A1 (en) 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4] oxazin-3-amine derivatives 5-(3-)-5--5,6--2h-[1,4]-3-
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2011157722A3 (en) Solid ivabradine-containing composition
WO2010001257A3 (en) Novel solid state forms of laquinimod and its sodium salt
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2010098583A3 (en) Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
WO2014049585A3 (en) Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2012116254A3 (en) Chrysophaentin analogs that inhibit ftsz protein
EP2742946A4 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
WO2014049586A3 (en) Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2013088384A3 (en) Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
EP2634183B8 (en) Method for preparing 1,3,5-trioxane
WO2013155465A8 (en) Substituted xanthine derivatives
EP2575465A4 (en) Salts of raltegravir
EP2634182A4 (en) Method for preparing 1,3,5-trioxane
WO2012007555A3 (en) New ziprasidone salts and methods of their formation
MX351994B (en) Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5 -carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino) -ethyl]-amide.
EP2789604A4 (en) Daidzein derivative, pharmaceutically acceptable salt and preparation method thereof, and pharmaceutical composition containing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743469

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11743469

Country of ref document: EP

Kind code of ref document: A2